As reported earlier this month, the Patented Medicine Prices Review Board has published a new draft of its guidelines and launched a 30-day written consultation period. While the law and regulations have already been passed, the implementation has been delayed from July 1, 2020 to Jan. 1, 2021. The new draft guidelines are in response […]
On May 12, Benefits Canada hosted a webinar to discuss the pharmaceutical industry’s efforts during the coronavirus crisis, as well as some key policy issues for Canadian insurers and their potential impact from the private-payer perspective. Since the end of April, 139 coronavirus treatments have been under investigation and Health Canada has approved several clinical trials […]
The Patented Medicine Prices Review Board will publish a new draft of its guidelines on June 15, followed by a written consultation period for 30 days. As a result, the amended regulations will be delayed from July 1, 2020 to Jan. 1, 2021. The PMPRB said more details on the next and final phase of […]
Private drug plans saw a slight uptick in costs in 2019 due to the increased use of specialty drugs and higher price points for traditional medications, according to Express Scripts Canada’s annual drug trends report. The report found private drug plan spending per claimant increased one per cent over 2018’s figures. Plans’ annual spend per claimant on […]
When it comes to benefits plan management, each case is individual, said Diana Godfrey, senior vice-president of human resources and corporate at Fidelity Canada, during a session at Benefits Canada’s 2020 Employers Cancer Care Summit on Mar. 3. “If employers think they have a program or policy that covers every situation, they may be mistaken.” […]
Taking a look at private drug plans in 2020, a number of trends are converging: spending on specialty drugs is continuing its upward trajectory, advancements in a number of lifechanging therapies are in the pipeline and policy developments are coming at both the federal and provincial levels. In the face of this potential storm, plan […]
The Canadian Life and Health Insurance Association is asking the Patented Medicine Prices Review Board to include workplace-related factors when it sets maximum prices for medications. In its submission for the PMPRB’s consultation on its draft guidelines, which were released in November, the CLHIA said the life and health insurance industry is very supportive of the […]
The Canadian Life and Health Insurance Association is asking the federal government to develop a strategy for access to high-cost drugs and to make flexible annuity options available for a variety of retirement savings vehicles. In its 2020 budget submission to Finance Minister Bill Morneau, the association called for the federal government to work with provincial and territorial governments and […]
The vast majority of pharmaceutical executives said they expect the incoming amendments to the Patented Medicine Prices Review Board to have a negative impact on their business plans in Canada, according to a new survey commissioned by Life Sciences Ontario. The survey, which drew on data from 46 respondents, including leaders from 36 Canadian and […]
The Canadian Life and Health Insurance Association is highlighting new retirement savings options and access to cheaper drugs in its priorities for the Quebec and Newfoundland and Labrador provincial budgets. In its submission to Newfoundland’s finance minister, the CLHIA called for the government to make pooled registered pension plans available in the province. Citing Statistics Canada data that […]